CytoTrack is a biotechnology startup with a focus on revolutionizing tumor cell detection through its advanced medical technology platform. The company's slogan, "Discover the Future of Tumor Cell Detection with Unparalleled Precision and Speed," encapsulates its commitment to innovation. CytoTrack's technology is designed to detect Circulating Tumor Cells (CTCs) in blood with unique capabilities, distinguishing itself by its ability to identify CTCs without relying on EpCAM enrichment or size-based filtration.
The standout feature of CytoTrack's platform is its exceptional scanning capacity, boasting the ability to scan 100 million cells per minute. Moreover, the CytoPicker feature allows for the isolation of single intact cells for downstream applications such as Single Cell PCR and FISH.
Initially developed as part of a research initiative at The National Hospital of Denmark and led by Professor John Philip, the technology was originally aimed at identifying FCMB (Foetal Cells in Maternal Blood). This project highlighted the inadequacy of conventional instruments such as flow cytometry and common fluorescent scanners in detecting rare fetal cells and their lack of molecular characterization capabilities.
Christian Caspersen created the CytoTrack technology to address the challenges of rare cell detection, and it has since been adapted for various applications, including the detection of CTCs. The startup was founded in 2004 and received a €50.00K grant investment on 10 January 2015 from EASME - EU Executive Agency for SMEs.
